Send this to a friend

Biostage scores $4M private investment, eyes turnaround

Two months after laying off more than 70 percent of its workforce and being delisted from Nasdaq, Holliston biotech Biostage announced on Thursday a $4-million private investment for more than half of the company's ownership.
“This agreement is a fantastic next step forward,” Biostage CEO Jim McGorry said in the announcement. “Our focus is on closing the private placement, funding and being back in operation at a more efficient si ...

Fields marked in red are required
Your name
Your email
Recipient addresses
(Separate multiple addresses with commas)

Personal message

ADVERTISEMENTS
Copyright 2017 New England Business Media